Get the Stockscreener App
9.85
12.29%
-1.38
After Hours:
9.90
0.05
+0.51%
Oric Pharmaceuticals Inc Stock (ORIC) Latest News
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright - Investing.com Australia
ORIC’s price-to-book ratio: An indicator of the company’s performance - US Post News
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up – What’s Next? - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Buy Rating from HC Wainwright - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Buy” Rating at Guggenheim - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 14.7%Time to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Given New $21.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating - TipRanks
ORIC Pharmaceuticals shares surge on potential data leak - Investing.com
Guggenheim Reiterates "Buy" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile - TipRanks
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Consensus Price Target from Analysts - MarketBeat
JPMorgan Chase & Co. Forecasts Strong Price Appreciation for ORIC Pharmaceuticals (NASDAQ:ORIC) Stock - Armenian Reporter
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6%Here's Why - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharma's Latest Talent Investment: Strategic Equity Awards Unveiled - StockTitan
There is no doubt that ORIC Pharmaceuticals Inc (ORIC) ticks all the boxes. - SETE News
ORIC Pharmaceuticals Inc (ORIC) may enjoy gains as insiders got busy in the recent days - Knox Daily
Daily Market Movement: ORIC Pharmaceuticals Inc (ORIC) Sees a -2.59 Decrease, Closing at 10.15 - The Dwinnex
ORIC Pharmaceuticals Inc (ORIC)’s stock chart: A technical perspective - US Post News
Citi maintains ORIC stock Buy rating, $13 target ahead of PFE data - MSN
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 15.6% – Still a Buy? - Armenian Reporter
ORIC Pharmaceuticals: Too Early To Commit, Despite Some Good Early Data - Seeking Alpha
SG Americas Securities LLC Sells 3,256 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
JPMorgan Chase & Co. Increases Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
ORIC Pharmaceuticals to Present at Three Major Healthcare Investor Conferences - StockTitan
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Up 5.6%Should You Buy? - MarketBeat
Research Analysts Issue Forecasts for ORIC FY2025 Earnings - Defense World
Analysts Set Expectations for ORIC FY2025 Earnings - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8%Should You Sell? - MarketBeat
Q2 EPS Estimate for ORIC Pharmaceuticals Reduced by Analyst - Defense World
Q2 EPS Forecast for ORIC Pharmaceuticals Reduced by Analyst - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.29 - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Oric Pharmaceuticals announces clinical supply agreement with Janssen - Yahoo Finance
Barclays PLC Raises Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Buy Rating from HC Wainwright - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from Wedbush - Defense World
ORIC Pharmaceuticals advances cancer drug trials - Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from Wedbush - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpHere's What Happened - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
ORIC Pharmaceuticals, Inc. Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLCwith EGFR Exon 20 Insertion Mutations - Marketscreener.com
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations - The Manila Times
ORIC® Pharmaceuticals Provides Early Phase 1b Combination - GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Supply Agreement to - GlobeNewswire
ORIC Pharma's Cancer Drug Shows Strong Early Results, Partners With J&J for Lung Cancer Trial - StockTitan
ORIC Partners with Janssen to Test ORIC-114 Combo Therapy for First-Line NSCLC Treatment - StockTitan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 8.8%Here's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):